Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated immune profiling identifies a coordinated T-cell activation and inflammatory signature in SLE.

Lupus science & medicine·2026
Same author

Immunopathogenesis of neuropsychiatric systemic lupus erythematosus: current insights into inflammatory and thrombotic pathways.

Journal of neuroinflammation·2026
Same author

The OEGMA-based hydrogel is active against all species of the ESKAPE pathogens, Streptococcus mutans and the pathogenic yeast Candida albicans.

Scientific reports·2026
Same author

AI-Designed Cyclic Peptides Enable Controllable Modulation of the CD28 Immune Checkpoint.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Comparison of Protein-Glycosaminoglycan Interactions in ff14sb/GLYCAM06j-1 and CHARMM36m Force Fields.

Journal of chemical information and modeling·2026
Same author

Physicochemical Characteristics of Amphipathic Peptides and Their Cytotoxic Effects on Cancer and Normal Cell Lines.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jan 6, 2026

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

CD160-Derived Peptide as a Bidirectional Inhibitor Toward Immune Checkpoints BTLA/HVEM and HVEM/LIGHT.

Magdalena Lipińska1, Piotr Ciura1, Simon Gumpelmair2

  • 1Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308 Gdańsk, Poland.

Journal of Medicinal Chemistry
|November 30, 2025
PubMed
Summary

Researchers developed peptide inhibitors targeting immune checkpoints. Peptide A5 effectively blocks BTLA/HVEM and HVEM/LIGHT interactions, showing potential for treating immune disorders.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.3K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.2K

Related Experiment Videos

Last Updated: Jan 6, 2026

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

3.3K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.2K

Area of Science:

  • Immunology
  • Molecular Biology
  • Drug Discovery

Background:

  • Immune checkpoints like BTLA and HVEM regulate immune responses.
  • HVEM interacts with both BTLA and CD160, making it a potential therapeutic target.
  • Targeting the overlapping binding sites could yield novel inhibitors.

Purpose of the Study:

  • To design and evaluate peptide inhibitors targeting the HVEM binding interface.
  • To identify peptides that can disrupt BTLA/HVEM and potentially other HVEM interactions.
  • To explore the therapeutic potential of these inhibitors for immune-related disorders.

Main Methods:

  • Peptide synthesis based on CD160-derived fragments.
  • Surface Plasmon Resonance (SpS) analysis for HVEM binding affinity.
  • Enzyme-Linked Immunosorbent Assay (ELISA) and cell-based assays for inhibitory activity.
  • Molecular docking simulations to predict binding modes.

Main Results:

  • Peptide A5 demonstrated significant binding to HVEM.
  • A5 effectively inhibited the BTLA/HVEM interaction.
  • Molecular docking indicated A5 binds to HVEM at both BTLA and LIGHT interaction sites.
  • ELISA and cell-based assays confirmed A5 disrupts BTLA/HVEM and HVEM/LIGHT complex formation.

Conclusions:

  • Peptide A5 acts as a dual inhibitor of HVEM interactions.
  • A5 shows promise as a therapeutic agent for immune-related disorders.
  • Targeting HVEM interactions offers a novel strategy for immune modulation.